

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

HEK-Blue IFN-alpha/beta

RRID:CVCL_KT26

Type: Cell Line

Proper Citation

InvivoGen Cat# hkb-ifnab, RRID:CVCL_KT26

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_KT26

Proper Citation: InvivoGen Cat# hkb-ifnab, RRID:CVCL_KT26

Description: Cell line HEK-Blue IFN-alpha/beta is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Female

Comments: Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the ISG54 promoter (InvivoGen=hkb-ifnab)., Characteristics: Designed to detect bioactive human type I IFNs by monitoring the activation of the ISGF3 pathway (InvivoGen=hkb-ifnab).

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: HEK-Blue IFN-alpha/beta

Synonyms: HEK-Blue IFN-a/b

Cross References: InvivoGen:hkb-ifnab, Wikidata:Q54882307

ID: CVCL_KT26

Vendor: InvivoGen

Catalog Number: hkb-ifnab

Hierarchy: cvcl_0045

Record Creation Time: 20250423T100357+0000

Record Last Update: 20260905T185115+0000

Ratings and Alerts

No rating or validation information has been found for HEK-Blue IFN-alpha/beta.

No alerts have been found for HEK-Blue IFN-alpha/beta.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jin Z, et al. (2026) Development of a novel tyrosine kinase 2 inhibitor ARTS-011 and its first-in-human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects. British journal of pharmacology, 183(11), 3074.

Amendolara R, et al. (2025) IFN- γ Neutralizing Antibodies Distinguish LADA From Early-onset Type 1 Diabetes. The Journal of clinical endocrinology and metabolism, 110(9), 2565.

Ng NKL, et al. (2025) Mechanism of Initial Favorable Response to Decitabine in TP53-Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(14), 3048.

Gómez-Bañuelos E, et al. (2024) Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE. Cell reports. Medicine, 5(5), 101569.

Chang F, et al. (2024) Development of nitroalkene-based inhibitors to target STING-dependent inflammation. Redox biology, 74, 103202.

Bradford HF, et al. (2023) Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFN γ and B cell subsets. Cell reports. Medicine, 4(1), 100894.

Morell M, et al. (2022) SIDT1 plays a key role in type I IFN responses to nucleic acids in plasmacytoid dendritic cells and mediates the pathogenesis of an imiquimod-induced psoriasis model. EBioMedicine, 76, 103808.

Metz PJ, et al. (2020) Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling. Cell reports, 30(6), 1935.

Pham TNQ, et al. (2019) Flt3L-Mediated Expansion of Plasmacytoid Dendritic Cells Suppresses HIV Infection in Humanized Mice. Cell reports, 29(9), 2770.

Ritchie C, et al. (2019) SLC19A1 Is an Importer of the Immunotransmitter cGAMP. *Molecular cell*, 75(2), 372.